Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Top Cited Papers
Open Access
- 16 January 2014
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 123 (3), 317-325
- https://doi.org/10.1182/blood-2013-10-529974
Abstract
Key Points A novel recombinant factor VIII with prolonged half-life, rFVIIIFc, was developed to reduce prophylactic injection frequency. rFVIIIFc was well-tolerated in patients with severe hemophilia A, and resulted in low bleeding rates when dosed 1 to 2 times per week.Keywords
This publication has 25 references indexed in Scilit:
- Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patientsBlood, 2013
- Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion proteinJournal of Thrombosis and Haemostasis, 2013
- Antibody formation and specificity in Bethesda‐negative brother pairs with haemophilia AHaemophilia, 2012
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patientsBlood, 2012
- A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A managementJournal of Thrombosis and Haemostasis, 2012
- F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicityHaemophilia, 2011
- Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importanceHaemophilia, 2009
- FcRn: the neonatal Fc receptor comes of ageNature Reviews Immunology, 2007
- FDA Workshop on factor VIII inhibitors held at the NIH, Bethesda, MA on 21 November 2003Haemophilia, 2004
- Barriers to compliance with prophylaxis therapy in haemophiliaHaemophilia, 2001